No clinically significant pharmacokinetic interaction is expected with efavirenz and levofloxacin as levofloxacin is metabolised to a very small extent. When compared to historical data for levofloxacin alone, coadministration of efavirenz (600 mg/day) with levofloxacin (500 mg once daily) resulted in no alteration in systemic exposure to levofloxacin (n=12). However, levofloxacin has a known risk of QT prolongation and/or TdP on the CredibleMeds.org website. Efavirenz was shown to prolong the QT interval above the regulatory threshold of concern in homozygous carriers of the CYP2B6*6/*6 allele (i.e. 516T variant in the gene encoding CYP2B6). The European product label for efavirenz contraindicates coadministration with a drug with a known risk of Torsade de Pointes whereas the American product label for efavirenz recommends that alternatives should be considered. As the potential risk of a QT interval prolongation relates specifically to homozygous carriers of CYP2B6*6/*6 and given the accumulated years of safety data with efavirenz and such drugs, the contraindication is not reflected in the colour coding of this interaction summary.